{
    "clinical_study": {
        "@rank": "119378", 
        "arm_group": {
            "arm_group_label": "Treatment with Lacrima medical device", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The study will assess the safety, tolerability and feasibility of Lacrima investigational\n      medical device to treat dry eye patients"
        }, 
        "brief_title": "Pilot Study to Clinical Evaluate Device Prototypes in Dry Eye Patients", 
        "condition": "Dry Eye Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          1. Male or female, 18 years of age and over at screening\n\n          2. Diagnosis of mild to moderate Dry Eye, as defined by:\n\n               1. Positive corneal fluorescein staining , defined as a corneal punctate\n                  fluorescein staining score of \u22653 in either eye by the National Eye Institute\n                  evaluation scale summed over 5 areas, each with a 0-3 scoring scale; AND\n\n               2. Schirmer Test score (with anesthesia, 5 minutes < 5 mm either eye) ; AND\n\n               3. OSDI score of \u226512 and OSDI score of <33\n\n        Main Exclusion Criteria:\n\n          1. Persistent intraocular inflammation or infection including conjunctivitis at the time\n             of the study or 2 weeks prior to study start.\n\n          2. Any concomitant active or history of eye disease including, but not limited to lid\n             abnormalities, nasolacrimal obstruction, active ulcer, glaucoma or ocular herpes\n             simplex virus infection\n\n          3. Patients currently using topical steroidal or anti-inflammatory eye drops for 1 month\n             prior to screening\n\n          4. Receipt of any type of topical artificial eye drops within 3 days prior to screening\n\n          5. Receipt of topical cyclosporine eye drops within 3 months prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01957670", 
            "org_study_id": "LM001"
        }, 
        "intervention": {
            "arm_group_label": "Treatment with Lacrima medical device", 
            "intervention_name": "Lacrima medical Prototypes", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Keratoconjunctivitis Sicca", 
            "Dry Eye Syndromes"
        ], 
        "lastchanged_date": "September 30, 2013", 
        "location": {
            "contact": {
                "email": "dr.levinger@gmail.com", 
                "last_name": "Elia Levinger, MD", 
                "phone": "+972-3-6973408"
            }, 
            "facility": {
                "address": {
                    "city": "Tel Aviv", 
                    "country": "Israel", 
                    "zip": "64239"
                }, 
                "name": "Tel Aviv Sourasky Medical Center, Israel"
            }, 
            "investigator": {
                "last_name": "Elia Levinger, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot, Open-label, Single-Arm Study Designed to Clinically Evaluate Various Lacrima Medical Device Prototypes in Adult Patients With Dry Eye Syndrome", 
        "overall_contact": {
            "email": "yaelkenan@lacrima-med.com", 
            "last_name": "Yael Kenan, Ph.D", 
            "phone": "972-3-9085028"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: The Israel National Institute for Health Policy Research and Health Services Research", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Lower Tear Meniscus Height using Optical Coherence Tomography", 
            "safety_issue": "No", 
            "time_frame": "up to 8 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957670"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Visual Analog Scale score", 
            "safety_issue": "Yes", 
            "time_frame": "up to 8 hours"
        }, 
        "source": "Lacrima Medical LTD", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lacrima Medical LTD", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}